FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome
The FDA has approved Avlayah (tividenofusp alfa-eknm) for the treatment of neurologic manifestations in specific patients with Hunter syndrome (Mucopolysaccharidosis type II).
This approval affects manufacturers of enzyme replacement therapies, clinical teams treating Mucopolysaccharidosis type II, and regulatory professionals managing orphan drug or neurologic therapy portfolios.
The approval provides a targeted therapeutic option for the neurologic manifestations of Hunter syndrome, a condition with significant unmet needs. For regulatory professionals, this reflects the ongoing utilization of specialized biologic pathways for rare lysosomal storage disorders. The source suggests a narrow indication scope ('certain individuals'), which may necessitate precise labeling and diagnostic alignment.
Regulatory and clinical teams should review the specific indications for Avlayah to determine the criteria for 'certain individuals' with Hunter syndrome. Pharmacovigilance departments should prepare post-market surveillance protocols for this new molecular entity.
The U.S. Food and Drug Administration approved Avlayah (tividenofusp alfa-eknm) to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II).
Open in openFDA / FDA.gov